Ferrum Health Inc., of San Francisco, is looking to prevent medical errors with the help of artificial intelligence (AI). That caught the eye of Sutter Health, a not-for-profit health care network in Northern California. To that end, the two have unveiled the debut of Ferrum's AI-powered platform as the system to deliver more consistent care to patients.
PDC*Line Pharma SA raised €13.9 million (US$15.4 million) in a series B round plus another €6.1 million in loans and grants from the Walloon region of Belgium to take its allogeneic cell-based cancer immunotherapy, PDC*lung-01, into a phase I/II trial in patients with metastatic lung cancer.
It is equally fair to say that lung cancer treatment has come a long way, and that it has a long way to go. Speaking at a joint conference by the International Association for the Study of Lung Cancer and the American Association for Cancer Research on lung cancer translational research, William Pao remembered the stark realities of being an oncology fellow at Memorial Sloan-Kettering Cancer Center just 20 years ago, when the main lung cancer “procedure” done by trainees was to get a DNR, or do-not-resuscitate order, from their patients.
SAN DIEGO – Allele-specific KRAS inhibitors are “the most exciting change coming down the pike for treating KRAS-mutant tumors in the near future,” Ferdinandos Skoulidis said at the sixth joint conference by the American Association for Cancer Research and the International Association for the Study of Lung Cancer meeting.
Transgene SA is quitting development of one of its lead therapeutic vaccines after a combination of the candidate, TG-4010, with chemotherapy and Opdivo missed its primary endpoint in a phase II trial evaluating the combination as a first-line treatment for certain advanced non-squamous non-small-cell lung cancers.
